AXSM (Axsome Therapeutics) Float Percentage Of Total Shares Outstanding: 63.86% (As of Jun. 27, 2026)


AXSM Axsome Therapeutics Inc AXSM
52 GF Score
Price $241.67
GF Value $220.41
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Axsome Therapeutics Float Percentage Of Total Shares Outstanding?

Axsome Therapeutics AXSM +1.83% 52 Float Percentage Of Total Shares Outstanding is 63.86% as of Jun. 27, 2026. GuruFocus rates AXSM with a GF Score™ of 52/100 and a GF Value™ of $220.41 (Fairly Valued). The stock has 4 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Axsome Therapeutics's float shares is 32.86 Mil. Axsome Therapeutics's total shares outstanding is 51.46 Mil. Axsome Therapeutics's float percentage of total shares outstanding is 63.86%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Axsome Therapeutics's Insider Ownership is 0.34%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Axsome Therapeutics's Institutional Ownership is 81.86%.

AXSM
52GF Score
Axsome Therapeutics Inc AXSM
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Axsome Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Axsome Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=32.86/51.46
=63.86%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 63.86% mean?
Axsome Therapeutics (AXSM) has a Float Percentage Of Total Shares Outstanding of 63.86% as of Jun. 27, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Axsome Therapeutics and its competitors.
Is Axsome Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Axsome Therapeutics' current Float Percentage Of Total Shares Outstanding is 63.86%. Overall, Axsome Therapeutics has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Float Percentage Of Total Shares Outstanding compare to IONS and EXEL?
Axsome Therapeutics' Float Percentage Of Total Shares Outstanding of 63.86% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Axsome Therapeutics and its competitors. Axsome Therapeutics's current Float Percentage Of Total Shares Outstanding is 63.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (AXSM) is currently considered Fairly Valued. The stock's GF Value™ is $220.41, compared to a current price of $241.67 — trading 9.6% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 63.86%. Axsome Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Axsome Therapeutics (AXSM), the current Float Percentage Of Total Shares Outstanding is 63.86% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axsome Therapeutics (AXSM) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of $241.67 is trading 9.6% above its estimated GF Value™ of $220.41. GuruFocus considers Axsome Therapeutics to be Fairly Valued.

Key valuation signals for AXSM:

  • Float Percentage Of Total Shares Outstanding: 63.86%
  • GF Value™: $220.41 vs. price of $241.67 (9.6% above fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axsome Therapeutics Business Description

Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score

Get the complete analysis for AXSM

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$241.67
Price
$220.41
GF Value